Watch Hubei Huaqiang High-Tech Co. Ltd. A for free: we tell you when fair value or trend changes.

Hubei Huaqiang High-Tech Co. Ltd. A (688151) fair value: what the stock is really worth

As of Oct 28, 2026: fair value (intrinsic value) of Hubei Huaqiang High-Tech Co. Ltd. A stock ¥7.61, price ¥16.59, upside -54.1%, quality 59 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value 30%+ above price?No
Quality 50+?Yes
In an uptrend?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100004Z48

Some data Oct 27, 2026

Hubei Huaqiang High-Tech Co. Ltd. A

688151 · SHG

Stretched ValuationStrong overvaluation with only moderate quality.

Our calculation puts a fair price 54% below what the stock costs today.

Generates free cash flow

Quality 59/100

Thin margins · 7.2% net margin (TTM)

0.3% dividend yield · Token dividend

Some data

Fair value ¥7.61 · Strongly overvalued (−54.1%)

Weak Growth (revenue 5y −5.5 %/yr in CNY)

Trails peers (2/11)

Narrow moat 23/100 · thin data

26 models, one by onewith weight and evidence Growth analysisrevenue history, year by year Quality 59/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch Hubei Huaqiang High-Tech Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.

How to read this chart

59‑month range ¥11.23 – ¥42.49 · the ¥16.59 price screens above the ¥7.61 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.

Follow Hubei Huaqiang High-Tech Co. Ltd. A in your weekly email

Every Wednesday you see whether Hubei Huaqiang High-Tech Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hubei Huaqiang High-Tech Co., Ltd. research, develops, produces, and sells special protective equipment, pharmaceutical packaging, and medical devices in China. The company operates as a chemical defense military enterprise in special protection.

Show moreShow less

It offers personal protective equipment, such as anti-virus clothing and boot covers, and gas masks; collective protective equipment, comprising cooperative supporting and demobilized troops products, pre-filters, air inlet components, particle filters, filter absorbers, poison filter ventilation devices, and collective protection system equipment; and chemical defense equipment for national civil air defense projects, such as civil air defense filters and doors, and impregnated carbon.

It also provides pharmaceutical packaging and medical devices, such as medicinal butyl rubber stoppers, multi-layer co-extruded films, aluminum-plastic covers, medical masks, and medical protective clothing; conventional and film-coated rubber stoppers, and rubber components for prefilled syringes; and medical disposable protective clothing, disposable medical masks, medical surgical and protective masks, and other medical protective products.

In addition, the company engages in business and manufacturing activities. Hubei Huaqiang High-Tech Co., Ltd. was founded in 2001 and is headquartered in Yichang, China.

Stock analysis

Hubei Huaqiang High-Tech Co. Ltd. A (688151) currently trades at ¥16.59, while our model-based Fair Value estimate is ¥7.61, 54.1% below the price, so the stock looks overvalued today.

Valuation

Bull case: the Asset-Based group reads highest at a median of ¥9.63 per share, and 1 of the 23 models we run sit above the ¥16.59 price.

Bear case: the Earnings-Based group reads lowest at ¥1.03, and 22 of the 23 models stay below the price. Data coverage for this calculation is medium.

Quality & growth

The Quality Score stands at 59/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Hubei Huaqiang High-Tech Co. Ltd. A reported revenue of 628M CNY in FY2025 versus 1.3B CNY in FY2021, a compound −16.2%/yr. Reported net income was 42.8M CNY in FY2025, compounding −39.5%/yr from FY2021.

Key figures

Market cap 5.7B CNY (≈ $859M) Small · P/E ratio 118.5 · P/S ratio 8.54 · EPS (TTM) ¥0.1400 · Dividend yield 0.3% · Net margin 7.2% · Return on equity 1.2% · Return on assets (EBIT) 1.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 30% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −42% fair-value upside, at −54%, 688151 screens richer than that median.

Fair Value models

Bear ¥7.61 Fair Value ¥7.61 Bull ¥7.61

Price ¥16.59 · Upside -54.1%

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.0695 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Best data coverage

FCF DCF ¥7.45 ¥7.49 ¥7.57 78

Growth DCF ¥7.45 ¥7.50 ¥7.57 75

Residual Income ¥8.11 ¥7.61 ¥7.28 74

All 23 models by family

DCF Models

FCF DCF ¥7.45 ¥7.49 ¥7.57 78

Owner Earnings ¥8.03 ¥8.26 ¥8.66 73

5Y Revenue Exit ¥7.53 ¥7.65 ¥7.83 69

5Y EBITDA Exit ¥8.36 ¥9.09 ¥10.05 72

5Y P/E Exit ¥8.38 ¥9.12 ¥10.00 67

10Y Revenue Exit ¥7.49 ¥7.57 ¥7.66 64

10Y EBITDA Exit ¥7.97 ¥8.40 ¥8.88 65

10Y P/E Exit ¥7.98 ¥8.42 ¥8.85 61

Earnings-Based

Graham-Dodd ¥0.8400 ¥1.03 ¥1.16 65

EPV ¥7.53 ¥7.56 ¥7.59 68

Dividend Discount

Gordon GGM ¥1.16 ¥1.25 ¥1.40 67

DDM Multi-Stage ¥1.16 ¥1.40 ¥1.71 65

Multiples

P/E Multiple ¥2.05 ¥2.73 ¥3.41 63

P/S Multiple ¥1.58 ¥2.11 ¥2.64 58

P/B Multiple ¥40.66 ¥54.21 ¥67.76 55

EV/EBIT ¥7.73 ¥7.87 ¥8.02 63

EV/EBITDA ¥9.32 ¥9.99 ¥10.66 64

EV/Revenue ¥7.61 ¥7.74 ¥7.87 52

Asset-Based

NCAV (Graham) ¥6.36 ¥9.63 ¥12.04 52

Growth DCF

Growth DCF ¥7.45 ¥7.50 ¥7.57 75

Economic Profit

Residual Income ¥8.11 ¥7.61 ¥7.28 74

ROIC Compounder ¥7.53 ¥7.56 ¥7.59 68

Growth Earnings

Growth-Adj P/E ¥1.44 ¥2.06 ¥2.68 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 59/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 17

How much profit the company makes from its sales and capital

Quality Growth 63

Are margins and returns getting better?

Cashflow 19

Do the profits arrive as real cash?

Financial strength 100

Debt, balance sheet and risk of trouble

Investment 94

Does it invest with discipline instead of growing at any price?

Low Volatility 74

How calm the share price moves, does not count

Momentum 30

Price trend of the last 3 to 12 months, does not count

Near the 52-week high 18

Distance to the 52-week high, does not count

New shares 82

Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 32/100

Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Revenue growth 1 year

+2.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+2.4%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−5.5%

Start year 2020 (pandemic)

Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−14.8%

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.

≈ −44.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year−45.0%

Dividend (yield on the price)0.3%

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.15% → 2%

⚠ Rate on operating basis: 2025 sits 90% above its own trend.

688151 screens overvalued: fair value 54% below the price. Compare with Intuitive Surgical, Inc →

Compare Hubei Huaqiang High-Tech Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 187 stocks

Beats the industry median on 2/11 measures

Overall it trails its industry peers.

Valuation

Quality Score 59 · Above median

Fair Value upside −54.1% · Bottom 25%

Profitability

Return on equity (12 months) 1.2% · Bottom 25%

Return on assets 0.9% · Below median

Net margin (12 months) 7.2% · Below median

Operating margin (12 months) −25.7% · Bottom 25%

Growth and dividend

Revenue growth (quarter YoY) 2.3% · Below median

Dividend yield (12 months) 0.3% · Bottom 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 118.5× · Priciest 25%

P/B 1.35× · Cheaper than median

P/S (12 months) 8.54× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)0 · sector 20

FUTURE (revenue growth)12 · sector 40

PAST (return on equity)5 · sector 28

HEALTH (low debt)0 · sector 96

DIVIDEND (yield)7 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value	Compare
Solventum Corporation SOLV	$82.98	$133.48	+61%	vs 688151
EssilorLuxottica Société anonyme EL	€181.80	€196.22	+8%	vs 688151
Medline Inc MDLN	$33.69	$29.06	−14%	vs 688151
Intuitive Surgical, Inc ISRG	$445.88	$353.90	−21%	vs 688151
Alcon Inc ALC	$69.42	$40.13	−42%	vs 688151
Becton, Dickinson and Company BDX	$196.39	$104.73	−47%	vs 688151
Straumann Holding STMN	CHF 97.66	CHF 45.50	−53%	vs 688151
West Pharmaceutical Services, Inc WST	$398.29	$137.81	−65%	vs 688151
Sartorius Stedim Biotech S.A DIM	€221.80	€54.82	−75%	vs 688151
Sartorius Aktiengesellschaft SRT	€227.00	€42.50	−81%	vs 688151

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator P/E Ratio Calculator PEG Ratio Calculator Graham Number Peter Lynch Formula DDM Calculator Intrinsic Value Intrinsic vs Extrinsic Value P/E Ratio by Sector

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hubei Huaqiang High-Tech Co. Ltd. A · Fair Value
¥7.61 −54%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/688151" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">Hubei Huaqiang High-Tech Co. Ltd. A · Fair Value</span><br><b style="font-size:20px">¥7.61</b> <span style="color:var(--red);font-weight:700;font-size:14px">−54%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "Hubei Huaqiang High-Tech Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688151

Frequently asked questions

Is Hubei Huaqiang High-Tech Co. Ltd. A (688151) overvalued or undervalued?

As of Oct 27, 2026, our model estimates a fair value of ¥7.61 versus a price of ¥16.59, about −54% upside (overvalued).

What is the fair value of 688151?

Our model-based fair value for Hubei Huaqiang High-Tech Co. Ltd. A is ¥7.61 (as of Oct 27, 2026), built from audited fundamentals. The current price: ¥16.59.

What is the quality score of 688151?

Hubei Huaqiang High-Tech Co. Ltd. A has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

Our model-based price target is the fair value of ¥7.61 (as of Oct 27, 2026) from 23 valuation models. It is a calculation from audited fundamentals, not an analyst target.

What is the Hubei Huaqiang High-Tech Co. Ltd. A stock forecast for 2026?

Our models put fair value at ¥7.61, about −54% upside versus a price of ¥16.59 (overvalued). The calculation is refreshed regularly with new filings.

What is the revenue of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

Hubei Huaqiang High-Tech Co. Ltd. A reported trailing-twelve-month revenue of about 670M CNY (latest available figure, as of Oct 27, 2026).

Does Hubei Huaqiang High-Tech Co. Ltd. A pay a dividend?

Hubei Huaqiang High-Tech Co. Ltd. A currently shows a dividend yield of 0.34% relative to its recent price (as of Oct 27, 2026).

What is the intrinsic value of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hubei Huaqiang High-Tech Co. Ltd. A it is ¥7.61 per share (as of Oct 27, 2026), against a price of ¥16.59. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).

Is Hubei Huaqiang High-Tech Co. Ltd. A stock overvalued or undervalued in 2026?

As of Oct 27, 2026, 688151 trades above its calculated fair value: price ¥16.59, fair value ¥7.61, a gap of about −54% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 688151?

No. The price is what the market pays today (¥16.59); the fair value is what the company's own numbers justify (¥7.61). For Hubei Huaqiang High-Tech Co. Ltd. A the two are ¥8.98 per share apart. That gap is exactly why we show both numbers side by side.

How much is Hubei Huaqiang High-Tech Co. Ltd. A worth?

The market values Hubei Huaqiang High-Tech Co. Ltd. A at about 5.7B CNY (market capitalisation, as of Oct 27, 2026). Per share that is ¥16.59; our models calculate a fair value of ¥7.61 per share.

What is the P/E ratio of 688151?

Hubei Huaqiang High-Tech Co. Ltd. A trades at a price-to-earnings ratio of 118.5 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥7.61 is built from several models across several years. Other multiples: P/B 1.4, P/S 8.5.

How solid is the balance sheet of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

Balance-sheet figures for Hubei Huaqiang High-Tech Co. Ltd. A (as of Oct 27, 2026): return on equity 1.2%. They feed the Quality Score of 59/100, which measures business quality independently of the share price.

How far is 688151 from its 52-week high?

Hubei Huaqiang High-Tech Co. Ltd. A trades at ¥16.59, about 30% below its 52-week high of ¥23.78 and 20% above the low of ¥13.79 (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of ¥7.61 is for.

Which stocks are comparable to Hubei Huaqiang High-Tech Co. Ltd. A?

From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is Hubei Huaqiang High-Tech Co. Ltd. A stock attractive at the current price?

The data as of Oct 27, 2026: price ¥16.59, calculated fair value ¥7.61 (−54%), Quality Score 59/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 688151 calculated?

We run Hubei Huaqiang High-Tech Co. Ltd. A through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥7.61, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 13.4 % above its aggregate fair value. Hubei Huaqiang High-Tech Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

The closing price on Oct 28, 2026 was ¥16.59. Our model-based fair value is ¥7.61, about −54% upside (overvalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with Hubei Huaqiang High-Tech Co. Ltd. A right now?

The price sits above even our optimistic bull case (¥7.61). The favourable scenario is already priced in. Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Hubei Huaqiang High-Tech Co. Ltd. A

How large is the market capitalisation of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

The market capitalisation of Hubei Huaqiang High-Tech Co. Ltd. A is 5.7B CNY (≈ $859M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

The price-to-sales ratio of Hubei Huaqiang High-Tech Co. Ltd. A is 8.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

Earnings per share at Hubei Huaqiang High-Tech Co. Ltd. A are ¥0.1400 (price ÷ EPS = P/E 118.5). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

The dividend yield of Hubei Huaqiang High-Tech Co. Ltd. A is 0.3% (payout 40.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

The net margin of Hubei Huaqiang High-Tech Co. Ltd. A is 7.2% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

The return on equity (ROE) of Hubei Huaqiang High-Tech Co. Ltd. A is 1.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

On an EBIT basis the return on assets of Hubei Huaqiang High-Tech Co. Ltd. A is 1.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

The operating margin of Hubei Huaqiang High-Tech Co. Ltd. A is −25.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

Revenue at Hubei Huaqiang High-Tech Co. Ltd. A is growing +2.3% versus a year earlier (3y avg +2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at Hubei Huaqiang High-Tech Co. Ltd. A (688151)?

Earnings per share at Hubei Huaqiang High-Tech Co. Ltd. A are growing +109% versus a year earlier. How much earnings per share grew versus a year earlier.

How much free cash flow does Hubei Huaqiang High-Tech Co. Ltd. A (688151) generate?

The free cash flow of Hubei Huaqiang High-Tech Co. Ltd. A is 5.6M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.

Free · no account needed

Watch Hubei Huaqiang High-Tech Co. Ltd. A in the live analysis

One click puts Hubei Huaqiang High-Tech Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.